Kymera Therapeutics stock has delivered a very strong 404.9% return over the past three years, yet the company currently screens as expensive on Simply Wall St’s valuation checks, raising the question of how much of the recent clinical progress is already reflected in the price.

• A roughly 4x gain over three years suggests investors have rapidly repriced Kymera Therapeutics on expectations that its drug pipeline can create meaningful long term value.
• Faster than expected enrollment in the KT-621 Phase 2b trial can support optimism on future revenue potential, while sizeable insider share sales may remind investors that clinical and execution risks are still meaningful.
• With Kymera Therapeutics scoring 1 out of 6 on the broader valuation checks, the stock currently appears expensive rather than coming across as a clear bargain.

The issue now is whether Kymera Therapeutics’ recent surge and rich valuation metrics leave enough room for investors to be compensated for the risks still ahead in its development pipeline.

Does Kymera Therapeutics Look Pricey on Book Value?

For a clinical stage biotech like Kymera Therapeutics, the P/B ratio is often a useful shorthand for how much investors are paying relative to the company’s net assets and research platform.

Kymera Therapeutics trades at a P/B of 6.1x, compared with a Biotechs industry average of about 2.7x and a peer average around 7.7x. That places the stock at a sizeable premium to the broader industry, even though it remains somewhat below the narrower peer group. The gap to the sector indicates that investors are paying materially more for each dollar of Kymera Therapeutics’ book value than for many other biotech stocks.

Despite the market’s positive response to faster KT-621 trial enrollment, this higher P/B indicates that Kymera Therapeutics is priced more aggressively relative to the typical biotech company on this metric.

On the P/B multiple, Kymera Therapeutics stock currently screens as overvalued compared with the wider Biotechs industry.

The Kymera Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St’s Narratives for Kymera Therapeutics pick up from this valuation puzzle by spelling out which assumptions on future growth, margins and earnings would need to hold for Kymera Therapeutics' stock to be worth meaningfully more or less than it is today, and they sit on the company’s Community page. Each narrative links a particular fair value estimate to a clear story about the company's potential catalysts and risks, so you can track over time which version of events appears to be unfolding.

If you have a number driven view on whether Kymera Therapeutics' faster KT-621 trial enrollment and recent insider selling truly support today's valuation, consider adding your own Narrative to the Simply Wall St community and set out the case in a way others can track as new data lands.

Do you think there's more to the story for Kymera Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Kymera Therapeutics, the key issue now is that the stock screens as overvalued on market multiples, with the broader valuation checks registering as weak. After such a sharp move, expectations around the drug pipeline and future commercialisation are already demanding, leaving less room for error.

From here, the debate between bulls and bears largely turns on whether Kymera Therapeutics can convert its current clinical momentum into durable revenue without major setbacks that challenge those expectations or force a reset in the valuation multiple investors are willing to pay.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.